Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences (CRBU) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $4.3 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 47.23% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 million (down 47.23% YoY) and the FY2025 annual result came in at $4.3 million, down 47.23% from the prior year.
• Non-Current Deferred Tax Liability climbed to $4.3 million in Q4 2025 per CRBU's latest filing, from $548000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $9.3 million in Q4 2023 and bottomed at $155000.0 in Q2 2021.
• The 5-year median for Non-Current Deferred Tax Liability is $476000.0 (2021), against an average of $1.5 million.
• The widest annual swing landed in 2023, when Non-Current Deferred Tax Liability soared 2345.14%; it then sank 47.23% in 2025.
• Tracing CRBU's Non-Current Deferred Tax Liability over 5 years: stood at $476000.0 in 2021, then fell by 19.96% to $381000.0 in 2022, then soared by 2345.14% to $9.3 million in 2023, then decreased by 13.24% to $8.1 million in 2024, then plunged by 47.23% to $4.3 million in 2025.
• Per Business Quant, the three latest CRBU Non-Current Deferred Tax Liability figures stand at $4.3 million (Q4 2025), $548000.0 (Q3 2025), and $548000.0 (Q2 2025).

Peer Comparison